DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency.
This year’s conference will have a special focus on emergency and hospital neurology. The AAN Summer Conference will cover the most critical and up-to-date information for neurologists and advanced practice providers and the curriculum covers the latest in clinically relevant scientific advances and case-based updates in all important neuro-hospitalist and neurocritical care topics.
The company will discuss the novel mechanism of DM199/KLK1 therapy and its ReMEDy2 phase 2/3 clinical trial in acute ischemic stroke with attending neurologists, stroke coordinators and emergency medicine attendees.
Any conference attendees wanting to learn more about DM199 or the ReMEDy2 trial should stop by the DiaMedica booth for enrollment details.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.